HDAC9 and mature T-cell and NK-cell non-Hodgkin lymphoma: In 2014, belinostat, also known as PXD101, which inhibits class I and II HDACs with nanomolar IC50 values, was the third HDAC inhibitor approved by the U.S. FDA to treat relapsed/refractory (RR) PTCL.